A University of California, Irvine patient with glioblastoma recently received an experimental cancer vaccine from the U.S. subsidiary of Brussels-based Epitopoietic Research Corp. (ERC-USA). While most cases of patients receiving experimental medical treatment are not particularly newsworthy, this one was.
Last week, the American Cancer Society released its annual Facts and Figures report, showing that we continue to make exceptional progress against cancer, most notably with a 27 percent decline in the death rate across all cancer types over the last 25 years.
In my twenty-two years of practicing medicine, I have observed the evolution of genomic testing and its increasing utility in oncology.
Study shows DNA biomarker can be used to predict outcomes for high risk low grade gliomas
In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.
Historically, oncology drug development has evolved on what may seem to be a different planet, at least relative to mainstream clinical pharmacology.
I remember the day I met Margaret “Peg” Geisler, who has now been living with breast cancer for 40 years, and with metastatic disease for 36 of those years.
In its just-published guideline on screening for colorectal cancer, the American Cancer Society revised its 2008 CRC screening guidelines, recommending that screening begin at age 45 instead of 50.
As I read the latest offering from the US Preventive Services Task Force, this time another encyclical on prostate screening, I felt a recurrence of the extreme irritation left over from the last time they wasted my (and their) time. Borrowing from Molière's “The Imaginary Invalid”, I conceived an Imaginary Interview with an un-named representative of this band of bozo's that seem to have few boundaries, a high level of comfort in wasting taxpayer dollars and editorial space, and who seem set on providing useless homilies that, at best, provide no value. This is couched as a Paul Goldberg-style low-key interview… and so the play begins:
Fourteen years ago, I was recruited to the University of Miami to develop a program in cancer disparities.
